Company / Operating Cash Flow
Xenetic Biosciences, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$2.8M
FY2025
5-year range
-$4.7M / -$2.8M
FY2021-FY2025
Trend
+31.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has increased for 3 consecutive years, from -$5M in FY2022 to -$3M in FY2025.
Based on SEC 10-K filings.
-$3M in FY2025.
Improved from -$5M to -$3M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Xenetic Biosciences, Inc.'s operating cash flow has grown for 3 consecutive years.
- In FY2025, operating cash flow increased 31.5% year-over-year.
- Peak operating cash flow was recorded in FY2018.
- Lowest operating cash flow in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.8M | +31.5% |
| FY2024 | -$4.1M | +11.5% |
| FY2023 | -$4.6M | +1.9% |
| FY2022 | -$4.7M | -11.0% |
| FY2021 | -$4.3M | +33.3% |
| FY2020 | -$6.4M | +1.0% |
| FY2019 | -$6.5M | -532.6% |
| FY2018 | $1.5M | +117.0% |
| FY2017 | -$8.8M | -65.8% |
| FY2016 | -$5.3M | +12.4% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026